Ipamorelin vs CJC-1295 / Ipamorelin (No DAC)

The primary similarity between Ipamorelin and the CJC-1295 / Ipamorelin (No DAC) blend lies in their shared objective: the stimulation of endogenous growth hormone synthesis and release from pituitary somatotrophs. Both contain Ipamorelin, a pentapeptide that functions as a highly selective agonist for the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. This shared component ensures that both research agents leverage the same GHRP pathway, which is distinct from the physiological GHRH pathway.

Consequently, research applications often overlap. Both are utilized in studies examining the downstream effects of elevated GH and subsequent Insulin-like Growth Factor 1 (IGF-1) signaling. These applications include in vitro and in vivo models of cellular proliferation, tissue repair, metabolic regulation, and age-related decline in endocrine function. The goal in both cases is to induce a biomimetic, pulsatile release of GH, rather than a sustained, non-physiological elevation, making them valuable for studies seeking to replicate endogenous pituitary function.

The fundamental difference between these two research agents is their composition and resulting mechanism of action. Ipamorelin is a single peptide molecule (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts exclusively on the GHSR-1a receptor. Its action isolates a single signaling pathway for GH release, allowing researchers to study the specific contributions of the ghrelin/GHSR-1a axis.

In contrast, CJC-1295 / Ipamorelin (No DAC) is a lyophilized blend of two distinct peptides. In addition to Ipamorelin, it contains Modified GRF (1-29), also known as CJC-1295 without Drug Affinity Complex (DAC). Mod GRF (1-29) is an analogue of GHRH that acts on the GHRH receptor (GHRH-R). Therefore, this combination product stimulates GH release via two separate and synergistic receptor systems simultaneously. This dual activation is hypothesized to produce a more robust and amplified GH pulse than either agent could elicit alone, more closely mimicking the body's natural coordinated release mechanism involving both GHRH and ghrelin.

This mechanistic difference leads to distinct pharmacokinetic profiles and research endpoints. While both Mod GRF (1-29) and Ipamorelin have relatively short biological half-lives (approx. 30 minutes and 2 hours, respectively), their combined use generates a potent but transient pulse. Ipamorelin alone provides a clean, single-pathway pulse, whereas the combination is designed to investigate the effects of a maximal, synergistic pulse. Furthermore, Ipamorelin is prized for its high selectivity, showing minimal to no effect on cortisol or prolactin release in preclinical studies, a characteristic maintained by the combination due to the selective nature of both its components.